Valeo Pharma
Financials
Estimates*
| CAD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.6m | 7.5m | 13.6m | 27.7m | 53.9m | 58.1m | 69.7m |
| % growth | 50 % | 14 % | 81 % | 105 % | 94 % | 8 % | 20 % |
| EBITDA | (3.4m) | (3.7m) | (11.9m) | (17.6m) | (10.9m) | (6.0m) | 4.3m |
| % EBITDA margin | (52 %) | (49 %) | (87 %) | (63 %) | (20 %) | (10 %) | 6 % |
| Profit | (3.6m) | (4.8m) | (14.2m) | (25.7m) | (27.8m) | (18.0m) | (12.4m) |
| % profit margin | (55 %) | (64 %) | (105 %) | (93 %) | (52 %) | (31 %) | (18 %) |
| EV / revenue | 2.3x | 6.6x | 4.8x | 1.9x | 0.3x | 0.1x | 0.6x |
| EV / EBITDA | -4.4x | -13.3x | -5.5x | -3.0x | -1.3x | -1.1x | 10.2x |
| R&D budget | <1m | - | <1m | <1m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | $3.1m | Post IPO Equity |
| N/A | $4.0m | Post IPO Equity | |
* | N/A | $6.9m | Post IPO Equity |
| N/A | $6.6m | Post IPO Debt | |
| N/A | $25.0m | Post IPO Debt | |
* | $40.0m | Post IPO Debt | |
* | $3.9m | Private Placement VC | |
* | N/A | $580k | Post IPO Debt |
* | $3.7m | Post IPO Debt | |
| Total Funding | $3.9m | ||
Related Content
Recent News about Valeo Pharma
EditValeo Pharma, founded in 2003, is a specialty pharmaceutical company based in Canada. The company focuses on licensing and acquiring Canadian rights to commercial-stage, innovative, and proprietary drugs. Valeo Pharma's portfolio includes nine commercialized products primarily in the therapeutic areas of Ophthalmology and Specialty Products. The company serves healthcare professionals and patients by providing advanced therapeutic solutions aimed at improving quality of life. Operating in the Canadian healthcare market, Valeo Pharma's business model revolves around acquiring rights to innovative drugs and bringing them to the Canadian market. Revenue is generated through the commercialization of these licensed and proprietary drugs. The company has a strong leadership team with extensive experience in the pharmaceutical industry, ensuring the successful development and growth of its product portfolio.
Keywords: specialty pharma, Canadian healthcare, innovative drugs, ophthalmology, therapeutic solutions, proprietary drugs, licensing, commercialization, healthcare professionals, quality of life.